Features | Partner Sites | Information | LinkXpress
Sign In
FOCUS DIAGNOSTICS, INC.
GLOBETECH PUBLISHING LLC
RANDOX LABORATORIES

Qiagen and Max Planck to Develop TB Molecular Diagnostic

By Labmedica International staff writers
Posted on 17 Jan 2012
Qiagen (Hilden, Germany) will collaborate with the Max Planck Institute for Infection Biology's (MPIIB; Berlin, Germany) department of immunology to develop a molecular diagnostic test for tuberculosis. The partners will develop a test aimed at assessing the risk of an individual with latent TB developing active TB disease during his lifetime. Financial terms of the alliance were not disclosed.

Both collaborators will cooperate in collecting, analyzing, and assessing data to identify genetic markers that indicate later development of active TB. Qiagen will be responsible for assay design and manufacturing, while MPIIB will provide access to its marker sets and develop new biosignatures.

Qiagen noted that as a follow-up to those who test positive for latent TB, the new test would be designed to enable early treatment before reactivation of the TB disease, when it becomes contagious and causes life-threatening respiratory illnesses and other diseases.

The assay, based on research conducted at MPIIB, is expected to be polymerase chain reaction (PCR)-based and target multiple biomarkers, said Qiagen. It will run on Qiagen's QIAsymphony platform and serve as a reflex test following Qiagen's QuantiFeron-TB Gold test for detection of latent TB. Qiagen will strengthen its infectious disease portfolio with development of the DNA-/RNA-based test that complements its QuantiFERON-TB Gold test for latent TB.

Resulting kits, which are not expected to be available before 2013, will be marketed by Qiagen.

"We believe that the combination of ‘pre-molecular’ and DNA-/RNA-based molecular testing technologies is the next-generation solution for screening and identifying infected individuals before they develop active TB disease," James Rothel, VP and head of scientific affairs at Qiagen, said in a statement. "This initiative has the potential to reduce the spread of infectious diseases significantly and also to generate cost savings by treating individuals before development of active TB."

Related Links:
Qiagen
Max Planck Institute for Infection Biology


DIASYS DIAGNOSTIC SYSTEMS
77 ELEKTRONIKA
KARL HECHT GMBH & CO KG

Channels

Genetic Tests

view channel
Image: Globoid cell leukodystrophy: Mulinucleated macrophages (\"globoid cells\") and loss of myelinated fibers in a case of Krabbe\'s leukodystrophy (Photo courtesy of Wikimedia Commons).

Advanced Next-Generation Sequencing Assay Kit Now Available for the Diagnosis of Leukodystrophy

An advanced next-generation sequencing (NGS) assay kit is now available to augment the use of MRI scans to diagnose the class of brain disorders known as leukodystrophies. Leukodystrophies are genetic... Read more

Hematology

view channel
Image: The ADVIA 2120 Hematology System (Photo courtesy of Siemens).

Preoperative Blood Cell Ratios Predict Endometrial Cancer Survival

The variations in systemic inflammatory response biomarker levels have been associated with adverse clinical outcome in various malignancies and the host response to malignant tumors is characterized by... Read more

Immunology

view channel
Image: Long-lived plasma cells have a distinctive \"fried egg\" appearance, containing bubble-like vacuoles or lipid droplets, which are generally rare in bone marrow cell samples (Photo courtesy of Emory University).

Long-Lived Antibody-Producing Cells Identified in Bone Marrow

A distinct set of long-lived antibody-producing cells have been identified in the human bone marrow that function as an immune archive. These cells keep a catalog of how an adult's immune system responded... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.